

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/055124 A1

(43) International Publication Date
25 March 2021 (25.03.2021)

(51) International Patent Classification:

A61K 31/135 (2006.01) A61P 25/24 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2020/046755

(22) International Filing Date:

18 August 2020 (18.08.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US2019/052210

	20 September 2019 (20.09.2019)	US
62/971,174	06 February 2020 (06.02.2020)	US
62/978,626	19 February 2020 (19.02.2020)	US
62/992,060	19 March 2020 (19.03.2020)	US
16/830,637	26 March 2020 (26.03.2020)	US
16/907,691	22 June 2020 (22.06.2020)	US

(71) Applicant: **AXSOME THERAPEUTICS, INC.** [US/US];
22 Cortlandt Street, 16th Floor, New York, New York
10007 (US).

(72) Inventor: **TABUTEAU, Herriot**; 22 Cortlandt Street, 16th
Floor, New York, New York 10007 (US).

(74) Agent: **JOHNSON, Brent A.** et al.; Maschoff Brennan,
100 Spectrum Center Drive, Suite 1200, Irvine, California
92618 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

(57) Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (*S*)-bupropion, enantiomerically enriched (*S*)-bupropion, or enantiomerically pure (*S*)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.

WO 2021/055124 A1